Next 10 |
2024-07-30 08:51:16 ET More on NeuroBo Pharmaceuticals NeuroBo Pharma prices private placement and direct offering to raise up to $70M NeuroBo says DA-1241, Wegovy combo shows potential in treating MASH Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals ...
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 PR Newswire CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transfo...
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...
2024-06-24 14:31:56 ET More on NeuroBo Pharmaceuticals NeuroBo says DA-1241, Wegovy combo shows potential in treating MASH Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for NeuroBo Pharmaceuticals Financial informatio...
NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in...
NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models PR Newswire DA-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide Lipid-...
2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...
2024-05-22 10:01:06 ET More on NeuroBo Pharmaceuticals NeuroBo Phase 2a study for MASH drug to proceed as planned NeuroBo stock jumps 14% on weight-loss drug update Seeking Alpha’s Quant Rating on NeuroBo Pharmaceuticals Historical earnings data for Ne...
NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone PR Newswire Data Will be Presented in Two Posters at the EASL Congress 20...
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 PR Newswire CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transfo...
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...